$MYO
MYOMO, INC. Stock $myo

$myo Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023007560 Filed on March 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.447M	$4.042M	$15.56M
YoY Change	-10.89%	0.25%	12.26%
Cost Of Revenue	$1.139M	$1.414M	$5.302M
YoY Change	-11.69%	55.52%	4596.31%
Gross Profit	$2.308M	$2.628M	$10.25M
YoY Change	-10.49%	-15.85%	-25.4%
Gross Profit Margin	66.95%	65.02%	65.91%
Selling, General & Admin	$4.502M	$4.357M	$18.44M
YoY Change	-3.32%	-13.56%	2.33%
% of Gross Profit	195.07%	165.83%	179.88%
Research & Development	$477.0K	$499.7K	$2.482M
YoY Change	-27.68%	-36.56%	-2.93%
% of Gross Profit	20.67%	19.02%	24.21%
Depreciation & Amortization	$48.63K	$49.06K	$192.8K
YoY Change	6.58%	-3.35%	32.06%
% of Gross Profit	2.11%	1.87%	1.88%
Operating Expenses	$4.979M	$4.857M	$20.93M
YoY Change	-6.35%	-16.66%	1.68%
Operating Profit	-$2.671M	-$2.229M	-$10.67M
YoY Change	-2.44%	-17.61%	56.1%
Interest Expense	$86.31K	$39.74K	$88.73K
YoY Change	-11025.82%	-873.15%	-678.43%
% of Operating Profit
Other Income/Expense, Net	$69.08K	-$1.100K	$21.12K
YoY Change	-8844.43%		-237.71%
Pretax Income	-$2.602M	-$2.191M	-$10.65M
YoY Change	-4.99%	-19.19%	3.58%
Income Tax	$42.41K	-$23.27K	$69.94K
% Of Pretax Income
Net Earnings	-$2.644M	-$2.167M	-$10.72M
YoY Change	-6.06%	-20.7%	3.37%
Net Earnings / Revenue	-76.72%	-53.63%	-68.92%
Basic Earnings Per Share	-$0.11		-$1.52
Diluted Earnings Per Share	-$0.11	-$0.29	-$1.52
COMMON SHARES
Basic Shares Outstanding	20.92M	7.055M	7.051M
Diluted Shares Outstanding	24.20M		7.051M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.264M	$5.346M	$5.346M
YoY Change	-28.43%	-65.56%	-65.56%
Cash & Equivalents	$9.264M	$5.346M	$5.346M
Short-Term Investments
Other Short-Term Assets	$535.6K	$573.5K	$573.5K
YoY Change	-43.08%	-35.89%	-35.89%
Inventory	$1.565M	$1.400M	$1.400M
Prepaid Expenses
Receivables	$1.548M	$1.896M	$1.896M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.91M	$9.215M	$9.215M
YoY Change	-22.24%	-51.73%	-51.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$190.7K	$194.3K	$703.0K
YoY Change	-31.77%	-29.43%	-22.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$115.3K	$132.5K	$132.5K
YoY Change	-42.07%
Other Assets	$111.0K	$111.0K	$111.0K
YoY Change	-0.34%	16.47%
Total Long-Term Assets	$824.0K	$946.5K	$946.6K
YoY Change	-39.94%	-5.68%	4.22%
TOTAL ASSETS
Total Short-Term Assets	$12.91M	$9.215M	$9.215M
Total Long-Term Assets	$824.0K	$946.5K	$946.6K
Total Assets	$13.74M	$10.16M	$10.16M
YoY Change	-23.59%	-49.43%	-49.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$906.8K	$1.323M	$1.323M
YoY Change	-10.6%	82.89%	82.89%
Accrued Expenses	$2.844M	$2.210M	$2.210M
YoY Change	-21.8%	-37.91%	-34.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.934M	$3.602M	$3.602M
YoY Change	-15.44%	-15.91%	-15.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$170.1K	$200.7K	$200.7K
YoY Change	-62.56%	-50.18%	-50.18%
Total Long-Term Liabilities	$170.1K	$200.7K	$200.7K
YoY Change	-62.56%	-50.18%	-50.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.934M	$3.602M	$3.602M
Total Long-Term Liabilities	$170.1K	$200.7K	$200.7K
Total Liabilities	$4.104M	$3.803M	$3.803M
YoY Change	-19.64%	-18.86%	-18.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$91.43M	-$88.78M
YoY Change	13.01%	13.68%
Common Stock	$101.0M	$95.11M
YoY Change		1.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$6.464K	$6.464K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	$9.632M	$6.359M	$6.359M
YoY Change
Total Liabilities & Shareholders Equity	$13.74M	$10.16M	$10.16M
YoY Change	-23.59%	-49.43%	-49.43%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.644M	-$2.167M	-$10.72M
YoY Change	-6.06%	-20.7%	3.37%
Depreciation, Depletion And Amortization	$48.63K	$49.06K	$192.8K
YoY Change	6.58%	-3.35%	32.06%
Cash From Operating Activities	-$1.817M	-$2.464M	-$10.23M
YoY Change	-21.01%	34.76%	7.18%
INVESTING ACTIVITIES
Capital Expenditures	$45.09K	$3.380K	$111.8K
YoY Change	-9.61%	-114.12%	-65.76%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$199.0K
YoY Change	-100.0%
Cash From Investing Activities	-$45.09K	-$3.380K	-$310.8K
YoY Change	-81.88%	-85.88%	-4.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.772M	376.9K	376.9K
YoY Change		-92.12%	-97.14%
NET CHANGE
Cash From Operating Activities	-1.817M	-2.464M	-10.23M
Cash From Investing Activities	-45.09K	-3.380K	-310.8K
Cash From Financing Activities	5.772M	376.9K	376.9K
Net Change In Cash	3.918M	-2.091M	-10.18M
YoY Change	-251.73%	-171.43%	-410.02%
FREE CASH FLOW
Cash From Operating Activities	-$1.817M	-$2.464M	-$10.23M
Capital Expenditures	$45.09K	$3.380K	$111.8K
Free Cash Flow	-$1.862M	-$2.468M	-$10.35M
YoY Change	-20.77%	36.74%	4.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001369290
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38109
CY2022	dei	Entity Registrant Name EntityRegistrantName	MYOMO, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-0944526
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	137 Portland St
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02114
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	996-9058
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	MYO
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	10010976
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20921712
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum, LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY, USA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5345967
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15524378
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1896163
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1960037
CY2022Q4	us-gaap	Inventory Net InventoryNet	1399865
CY2021Q4	us-gaap	Inventory Net InventoryNet	808308
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	573462
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	799164
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9215457
CY2021Q4	us-gaap	Assets Current AssetsCurrent	19091887
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	194283
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	275289
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	508743
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	632906
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	132489
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	0
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111034
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95330
CY2022Q4	us-gaap	Assets Assets	10162006
CY2021Q4	us-gaap	Assets Assets	20095412
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3179362
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3910639
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	353701
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	333380
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	48220
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	39145
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	20653
CY2021Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	249
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3601936
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4283413
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	200207
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	401622
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	498
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1246
CY2022Q4	us-gaap	Liabilities Liabilities	3802641
CY2021Q4	us-gaap	Liabilities Liabilities	4686281
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7750635
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6869753
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7750608
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6869726
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	775
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	687
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	95105071
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	93537807
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	43227
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60677
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88783244
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78062222
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	27
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	27
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	6464
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	6464
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6359365
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15409131
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10162006
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20095412
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15555229
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13856374
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5302133
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3544097
CY2022	us-gaap	Gross Profit GrossProfit	10253096
CY2021	us-gaap	Gross Profit GrossProfit	10312277
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2482489
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2557367
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18442811
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18022975
CY2022	us-gaap	Operating Expenses OperatingExpenses	20925300
CY2021	us-gaap	Operating Expenses OperatingExpenses	20580342
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10672204
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-10268065
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	88731
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1612
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1101
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-16948
CY2021	us-gaap	Depreciation Depreciation	145995
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1190494
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-66511
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21119
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15336
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10651085
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10283401
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69937
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	88928
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10721022
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10372329
CY2022	myo	Deemed Dividend On Discounting And Repricing Of Warrants DeemedDividendOnDiscountingAndRepricingOfWarrants	0
CY2021	myo	Deemed Dividend On Discounting And Repricing Of Warrants DeemedDividendOnDiscountingAndRepricingOfWarrants	-639953
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10721022
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11012282
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7051447
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7051447
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5830353
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5830353
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.89
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.89
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10721022
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10372329
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	103904
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-47987
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	103904
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47987
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10617118
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10420316
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11565374
CY2021	myo	Common Stock Issued For Warrants Exercised Net Of Offering Costs CommonStockIssuedForWarrantsExercisedNetOfOfferingCosts	349400
CY2021	myo	Common Stock Issued For Warrants Exercised CommonStockIssuedForWarrantsExercised	12067865
CY2021	myo	Proceeds From Issuances Under At Market Sales Facility Value ProceedsFromIssuancesUnderAtMarketSalesFacilityValue	1099800
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1096408
CY2021	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-47987
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10372329
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15409131
CY2022	myo	Proceeds From Issuance Of Prefunded Warrants In Conjunction With Public Offering ProceedsFromIssuanceOfPrefundedWarrantsInConjunctionWithPublicOffering	376858
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1190494
CY2022	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-103904
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10721022
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6359365
CY2022	us-gaap	Profit Loss ProfitLoss	-10721022
CY2021	us-gaap	Profit Loss ProfitLoss	-10372329
CY2022	us-gaap	Depreciation Depreciation	192799
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1096408
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-202
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15524378
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26075
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-66511
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	349828
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	189968
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-111755
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	19929
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-47445
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1046282
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	607400
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	118222
CY2022	myo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-224677
CY2021	myo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	323644
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15704
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-711898
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1113235
CY2022	myo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-406759
CY2021	myo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-92525
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19657
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2512
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-118060
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10233542
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9547695
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	111793
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	326462
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	199000
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-310793
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-326462
CY2022	myo	Proceedsfromissuancesunderequitylineofcreditnetofcosts Proceedsfromissuancesunderequitylineofcreditnetofcosts	376858
CY2021	myo	Proceedsfromissuancesunderequitylineofcreditnetofcosts Proceedsfromissuancesunderequitylineofcreditnetofcosts	0
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12067865
CY2022	myo	Proceeds From At The Market Offering Net Of Offering Costs ProceedsFromAtTheMarketOfferingNetOfOfferingCosts	0
CY2021	myo	Proceeds From At The Market Offering Net Of Offering Costs ProceedsFromAtTheMarketOfferingNetOfOfferingCosts	1099801
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	376858
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13167666
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-10934
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-10392
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10178411
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3283117
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15524378
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12241261
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5345967
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4889
CY2022	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	50000
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	5
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	225665
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	654091
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Note 1 — Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics (“O&P”) providers for which they are paid a fee. The Company sells the product to O&P providers around the world and the Veterans Health Administration ("VA"). The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Pursuant to an amended and restated certificate of incorporation, the Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of stock, consisting of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">65,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of undesignated Preferred Stock, par value of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Going Concern and Management Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company incurred net losses of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,721,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,372,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> during the years ended December 31, 2022 and 2021, respectively, and has an accumulated deficit of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">88,783,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">78,062,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">at December 31, 2022 and 2021, respectively. Cash used in operating activities was approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,234,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,548,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has historically funded its operations through financing activities, including raising equity and debt capital. In January 2023, the Company completed an equity offering under which it sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,169,074</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,830,926</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> pre-funded warrants at $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.325</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share, generating proceeds after fees and expenses of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. (See Note 13 - Subsequent Events for further discussion.) During the fourth quarter of 2022, the Company sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">692,914</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock under a Common Stock Purchase Agreement (the "Purchase Agreement") with Keystone Capital Partners ("Keystone"), generating proceeds after fees and expenses of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. (See Note 7 - Common Stock for further discussion.) During 2021, $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was received from the exercise of warrants, including $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in net proceeds in October 2021 from a transaction to induce the exercise of warrants issued in conjunction with its equity offering in February 2020 at a reduced exercise price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. These financing activities, in addition to funding of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million received from sales of common stock under an At Market Sales Facility, or ATM facility, with Alliance Global Partners ("AGP") during the year ended December 31, 2021 is enabling the Company to sustain its operations. Considering the Company's cash balance as of December 31, 2022 and net proceeds from the equity offering in January 2023 and its cash used from operations during the year ended December 31, 2022, management believes there is substantial doubt regarding its ability to continue as a going concern.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Management's operating plans are primarily focused on growing its revenues and limiting operating expenses through focusing its clinical and reimbursement efforts on patients with insurers that have previously reimbursed for the MyoPro. The Company believes the growth in its patient pipeline during 2022 provides an opportunity to accelerate its revenue growth in 2023. The Company has stopped activities geared toward increasing the number of payers that will reimburse for its products until the Company receives reimbursement for its products provided to Medicare Part B beneficiaries from the Centers for Medicare and Medicaid Services ("CMS"), or CMS states in intention to reimburse for its products. As a result, the Company has undertaken cost reduction activities, including the reduction of approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of its workforce in January 2023. This and other cost reduction efforts are expected to reduce its operating expense run-rate by approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">in 2023. With respect to CMS, the Company expects to meet with the medical directors of CMS's administrative billing contractors, referred to as the DME MAC's, before the end of the first quarter of 2023 to discuss coverage and reimbursement, and begin submitting claims on behalf of Medicare Part B beneficiaries as soon as practical thereafter. The Company's success is dependent upon reimbursement of its products by insurance companies and government-controlled health care plans such as Medicare and Medicaid in the United States and Statutory Health Insurance plans in Germany, which could prevent our revenues from growing to the level necessary to achieve cash flow breakeven. If public health restrictions on travel and patient interaction are broadly reinstated in 2023 due to new variants of COVID-19 and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">increasing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">infections in the U.S., that will have an adverse effect on the Company's business, and it is possible that the Company will need to raise additional capital to sustain its operations through 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company believes that it has access to capital resources through payment of the technology license fee associated with its joint venture in China, possible public or private equity offerings, exercises of outstanding warrants, additional debt financings, or other means; however, the Company may be unable to raise sufficient additional capital when it needs it or raise capital on favorable terms. As part of the Company's equity offering in January 2023, the Company agreed to not sell any shares of its common stock to Keystone under the Purchase Agreement or under its ATM Facility for a period of one year from the closing of the offering. The Company has remaining capacity under its Purchase Agreement with Keystone of approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million shares and approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million under its ATM Facility. However, due to its public float, the amount of securities the Company may sell from time to time under the registration statement which registered the ATM Facility may be subject to the limitations imposed by General Instruction I.B.6 of Form S-3. Further, selling the full $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million to Keystone under the Purchase Agreement requires approval from shareholders to sell shares in excess of the exchange cap under the rules of the NYSE American. Should the Company consider debt financing, such a transaction may require the Company to pledge certain assets and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness and may contain other terms that are not favorable to its stockholders or the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">If the Company is unable to obtain adequate funds on reasonable terms, the Company may be required to significantly curtail or discontinue operations or obtain funds by entering into financing agreements on unattractive terms. There can be no assurance that the Company will be successful in implementing its plans.</span></p>
CY2022Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	75000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	myo	Net Loss Income NetLossIncome	10721000
CY2021	myo	Net Loss Income NetLossIncome	10372000
CY2022Q4	myo	Accumulated Deficit AccumulatedDeficit	88783000
CY2021Q4	myo	Accumulated Deficit AccumulatedDeficit	78062000
CY2022	myo	Net Cash Provided By Used In Operating Activity NetCashProvidedByUsedInOperatingActivity	10234000
CY2021	myo	Net Cash Provided By Used In Operating Activity NetCashProvidedByUsedInOperatingActivity	9548000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12100000
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4800000
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain prior year amounts have been reclassified to conform to current year's presentation, which management does not consider to be material.</span></p>
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13856374
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	707183
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.</span></p>
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	633485
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	431894
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-66500
CY2022	myo	Percentage Of Direct Billing Channel Revenue Insures Represent PercentageOfDirectBillingChannelRevenueInsuresRepresent	0.44
CY2021	myo	Percentage Of Direct Billing Channel Revenue Insures Represent PercentageOfDirectBillingChannelRevenueInsuresRepresent	0.39
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	21200
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1500
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15555229
CY2022	myo	Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Ultimate Settlement IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponUltimateSettlement	0.50
CY2022	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	103900
CY2021	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	-48000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	194283
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	275289
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1164415
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1017841
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4069300
CY2021	us-gaap	Advertising Expense AdvertisingExpense	3587300
CY2021Q4	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	640000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	512028
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	176082
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	18971
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	23161
CY2022Q4	myo	Inventory Rental Units InventoryRentalUnits	51694
CY2021Q4	myo	Inventory Rental Units InventoryRentalUnits	62531
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	903581
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	584996
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	1486274
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	846770
CY2022Q4	myo	Inventory Reserve For Rental Units InventoryReserveForRentalUnits	86409
CY2021Q4	myo	Inventory Reserve For Rental Units InventoryReserveForRentalUnits	38462
CY2022Q4	us-gaap	Inventory Net InventoryNet	1399865
CY2021Q4	us-gaap	Inventory Net InventoryNet	808308
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	827768
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	192800
CY2021	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	146000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4350657
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	14803456
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	569681
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	723352
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	959228
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2188869
CY2022Q4	myo	Professional Fees Accrued Current ProfessionalFeesAccruedCurrent	124548
CY2021Q4	myo	Professional Fees Accrued Current ProfessionalFeesAccruedCurrent	108417
CY2022Q4	myo	Deferred Payroll Taxes Under Cares Act DeferredPayrollTaxesUnderCARESAct	0
CY2021Q4	myo	Deferred Payroll Taxes Under Cares Act DeferredPayrollTaxesUnderCARESAct	113423
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	234647
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	176281
CY2022Q4	myo	Accrued Liabilities Customer Deposit AccruedLiabilitiesCustomerDeposit	753232
CY2021Q4	myo	Accrued Liabilities Customer Deposit AccruedLiabilitiesCustomerDeposit	192501
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	538026
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	407796
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3179362
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3910639
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24088
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	51.2900
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23194
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9250
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.0700
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1452
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	50.9600
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	439
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0500
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	31447
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.5800
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3267
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23194
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1700
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.0000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3293
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.0400
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	249
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.1900
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29605
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.5000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	587
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17390
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.2600
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M19D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12392
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20229
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	54.9600
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M1D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	587
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.1718
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.1190
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0168
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0115
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2478
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0066
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1190494
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1096408
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2709159
CY2020Q4	myo	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	2709159
CY2020Q4	myo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	7.77
CY2020Q4	myo	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	7.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	273
CY2021	myo	Class Of Warrant Or Rights Expired ClassOfWarrantOrRightsExpired	273
CY2021	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice	194.10
CY2021	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePriceExercisable	194.10
CY2021	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod	-2015243
CY2021	myo	Class Of Warrant Or Rights Exercised ClassOfWarrantOrRightsExercised	-2015243
CY2021	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice	7.40
CY2021	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable	7.40
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	693643
CY2021Q4	myo	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	693643
CY2021Q4	myo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	8.76
CY2021Q4	myo	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	8.76
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	12614
CY2022	myo	Class Of Warrant Or Rights Expired ClassOfWarrantOrRightsExpired	12614
CY2022	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice	29.30
CY2022	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePriceExercisable	29.30
CY2022	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod	-666
CY2022	myo	Class Of Warrant Or Rights Exercised ClassOfWarrantOrRightsExercised	-666
CY2022	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice	0
CY2022	myo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	680363
CY2022Q4	myo	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	680363
CY2022Q4	myo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	8.30
CY2022Q4	myo	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	8.30
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0086
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18052725
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16067000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	25900
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	112900
CY2022Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	135000
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, MA expiring in August 2023, consisting of 9,094 square feet of office and laboratory space. In conjunction with entering into a lease in the same building for 3,859 square feet of space to be used for manufacturing, the Company agreed to lease its corporate headquarters space from the landlord after expiration of the sublease. Both leases expire in January 2025. In addition, it has a non-cancelable lease agreement for its office space in Fort Worth, TX expiring in 2025 with early termination available at the company’s discretion in 2023. Certain of the arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term
CY2022Q4	myo	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	508700
CY2022Q4	myo	Operating Lease Liabilities OperatingLeaseLiabilities	553900
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	411142
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	159872
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	67981
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	638995
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	85087
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	553908
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	353701
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	200207
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	553908
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	423036
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	234647
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	493203
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	372114
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3250
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29759
CY2022	us-gaap	Lease Cost LeaseCost	496453
CY2021	us-gaap	Lease Cost LeaseCost	401873
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	557500
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	275300
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.20
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.20
CY2022	myo	Product Warranty Period ProductWarrantyPeriod	P3Y
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	176281
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	119713
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	117986
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	79142
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	0
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	26735
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	59620
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	49309
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	176281
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10831796
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10494693
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	180711
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	211292
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10651085
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10283401
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2791239
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2038000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-615573
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-510000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	69937
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	88928
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	myo	Federal State And Local And Foreign Income Tax Expense Benefit FederalStateAndLocalAndForeignIncomeTaxExpenseBenefit	-3336876
CY2021	myo	Federal State And Local And Foreign Income Tax Expense Benefit FederalStateAndLocalAndForeignIncomeTaxExpenseBenefit	-2459072
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3406813
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2548000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69937
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	88928
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0560
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0521
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.0006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.0136
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0086
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0028
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0279
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.0591
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.0000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	311000
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	657076
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	900144
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	27000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	411258
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	648000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20444240
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17053000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20444240
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17053000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0
CY2022Q4	myo	Operating Loss Carry Forwards Annual Limitations OperatingLossCarryForwardsAnnualLimitations	281000
CY2022Q4	myo	Operating Loss Carryforwards Unutilized OperatingLossCarryforwardsUnutilized	437000
CY2022Q4	myo	Deferred Tax Asset And Valuation Allowance Adjusted To Reflect Federal Nol Unutilized DeferredTaxAssetAndValuationAllowanceAdjustedToReflectFederalNOLUnutilized	92000
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15
CY2022Q3	us-gaap	Revenues Revenues	1000000000.0
CY2022	myo	Valuation Allowance Deferred Tax Asset Decrease Increase Amount ValuationAllowanceDeferredTaxAssetDecreaseIncreaseAmount	3365000
CY2021	myo	Valuation Allowance Deferred Tax Asset Decrease Increase Amount ValuationAllowanceDeferredTaxAssetDecreaseIncreaseAmount	2548000
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0

Files In Submission

Name	View Source	Status
0000950170-23-007560-index-headers.html	Edgar Link	pending
0000950170-23-007560-index.html	Edgar Link	pending
0000950170-23-007560.txt	Edgar Link	pending
0000950170-23-007560-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
myo-20221231.htm	Edgar Link	pending
myo-20221231.xsd	Edgar Link	pending
myo-ex21_1.htm	Edgar Link	pending
myo-ex23_1.htm	Edgar Link	pending
myo-ex31_1.htm	Edgar Link	pending
myo-ex31_2.htm	Edgar Link	pending
myo-ex32_1.htm	Edgar Link	pending
myo-ex32_2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
myo-20221231_cal.xml	Edgar Link	unprocessable
myo-20221231_def.xml	Edgar Link	unprocessable
myo-20221231_lab.xml	Edgar Link	unprocessable
myo-20221231_pre.xml	Edgar Link	unprocessable
myo-20221231_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYO
MYOMO, INC. Stock $myo

2023 Q1 Form 10-K Financial Statement

#000095017023007560 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYO MYOMO, INC. Stock $myo

2023 Q1 Form 10-K Financial Statement

#000095017023007560 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYO
MYOMO, INC. Stock $myo